Bioerrodable, Resorbable, Or Dissolving Patents (Class 424/428)
  • Patent number: 11065151
    Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: July 20, 2021
    Assignee: ForSight Vision4, Inc.
    Inventors: Eugene de Juan, Jr., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
  • Patent number: 10988583
    Abstract: The present invention relates to the formation of gels. In particular, the present invention is directed to a method of forming a cross-linked polymer hydrogel using competitive ligand exchange.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: April 27, 2021
    Assignee: Nordovo Biosciences AS
    Inventors: David Charles Bassett, Armend Gazmeno Håti
  • Patent number: 10864218
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: December 15, 2020
    Assignee: ALLERGAN, INC.
    Inventor: Patrick M. Hughes
  • Patent number: 10716779
    Abstract: The present disclosure provides novel formulations for treating foot or hand pain by topically administering a sympathomimetic drug, particularly oxymetazoline, to the skin of the foot or hand.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: July 21, 2020
    Inventor: Jennifer L. Sanders
  • Patent number: 10561606
    Abstract: What is disclosed is a controlled release pharmaceutical composition comprising a biocompatible and bioerodible semi-solid gel comprising a triglyceride of ricinoleic acid, a gelling agent, bupivacaine and, optionally, a corticosteroid, an analgesic, or an anti-inflammatory agent.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: February 18, 2020
    Assignee: Mira Pharma Corporation
    Inventors: Hui Rong Shen, Na Gan
  • Patent number: 10441543
    Abstract: Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: October 15, 2019
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, James N. Chang, Michelle H. Luu
  • Patent number: 10434071
    Abstract: The present invention relates to a drug delivery system comprising a core and a shell in which the core comprises a hydrolytically degradable polymer X which polymer backbone comprises pendant ester and acid functionalities and in which the shell comprises a hydrolytic degradable polymer Y. The hydrolytic degradable polymers X and Y are different polymers. Polymer X further comprises amino-acids in the polymer backbone and degrades via zero order degradation kinetics for a period of at least 3 months. Polymer Y degrades via auto-acceleration degradation kinetics.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: October 8, 2019
    Assignee: DSM IP ASSETS, B.V.
    Inventors: George Mihov, Guy Draaisma, Silvana Rensina Antonnietta Di Silvestre, Tristan Handels
  • Patent number: 10369107
    Abstract: Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or IOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: August 6, 2019
    Assignee: The Johns Hopkins University
    Inventors: Peter J. McDonnell, Yasin A. Khan, Samuel K. Lai, Renata T. Kashiwabuchi, Ashley Behrens, Justin S. Hanes
  • Patent number: 10328086
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: June 25, 2019
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • Patent number: 10278919
    Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: May 7, 2019
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, James A. Burke, Rhett M Schiffman, Alazar N. Ghebremeskel
  • Patent number: 10272089
    Abstract: The use of methotrexate, e.g., repeated dosing or sustained-release formulations of methotrexate, for treating or reducing risk of proliferative vitreoretinopathy (PVR) or epiretinal membranes (ERM), e.g., after surgical vitrectomy to treat retinal detachment.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: April 30, 2019
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Dean Eliott, Tomasz P. Stryjewski
  • Patent number: 10220093
    Abstract: What is described is a semi-solid controlled release composition comprising a semi-solid lipid and bupivacaine in a solution or a homogenous suspension, methods of using the composition for treating a disease, and methods of manufacturing the composition.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: March 5, 2019
    Assignee: Mira Pharma Corporation
    Inventors: Hui Rong Shen, Na Gan
  • Patent number: 10195180
    Abstract: The present disclosure provides novel formulations for treating foot or hand pain by topically administering a sympathomimetic drug, particularly oxymetazoline, to the skin of the foot or hand.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: February 5, 2019
    Inventor: Jennifer L. Sanders
  • Patent number: 10188665
    Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: January 29, 2019
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Kelly M. Harrison
  • Patent number: 10143530
    Abstract: According to embodiments, a membrane with a flat or curved surface is provided for protection of intraocular tissues. The membrane can be used to cover the cornea for protecting corneal endothelial cells, to cover the anterior and posterior surface of the iris, or to cover the surface of the posterior capsule for separating the intraocular tissues. The membrane has a layered structure, which is composed of a collagen and a hydrophilic biopolymer or an organic polymer material. In particular, the membrane has high transparency and high water retention in a wet state.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: December 4, 2018
    Assignees: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE, NATIONAL TAIWAN UNIVERSITY HOSPITAL
    Inventors: Yu-Bing Liou, Hsiu-Ying Wang, Hsin-Yi Hsu, Wei-Li Chen, Chin-Tsung Huang, Hsin-Hsin Shen
  • Patent number: 10098884
    Abstract: The use of methotrexate, e.g., repeated dosing or sustained-release formulations of methotrexate, for treating or reducing risk of proliferative vitreoretinopathy (PVR) or epiretinal membranes (ERM), e.g., after surgical vitrectomy to treat retinal detachment.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: October 16, 2018
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Dean Eliott, Tomasz P. Stryjewski
  • Patent number: 9937130
    Abstract: Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or IOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: April 10, 2018
    Assignee: The Johns Hopkins University
    Inventors: Peter J. McDonnell, Yasin A. Khan, Samuel K. Lai, Renata T. Kashiwabuchi, Ashley Behrens, Justin S. Hanes
  • Patent number: 9925219
    Abstract: The invention provides multi-chamber encapsulated cell therapy cartridge devices that are capable of delivering biologically active molecules as well as methods of using these devices.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: March 27, 2018
    Assignee: Neurotech USA, Inc.
    Inventors: Konrad A. Kauper, John Fraser Mills, Megan Billings, Michael R. Rivera, Alline Monteiro Alcantara Lelis
  • Patent number: 9750751
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: September 5, 2017
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • Patent number: 9724293
    Abstract: A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: August 8, 2017
    Assignee: INTARCIA THERAPEUTICS, INC.
    Inventors: Rom Ezer Eliaz, Yuanpeng Zhang, Catherine Manya Rohloff, Eric William Weeks, Gunjan Junnarkar
  • Patent number: 9592242
    Abstract: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: March 14, 2017
    Assignee: Allergan, Inc.
    Inventor: Vernon G. Wong
  • Patent number: 9492316
    Abstract: Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: November 15, 2016
    Assignee: Allergan, Inc.
    Inventors: Alazar N. Ghebremeskel, Michael R. Robinson
  • Patent number: 9295753
    Abstract: A method for the producing a complex containing human or mammal's amniotic membrane/placental extract with or without collagen. Compositions containing the complexes and therapeutic methods using the complexes are provided. In addition, the invention relates to a method of controlling the absorption rates of amniotic membrane/extract and/or placental extract by combining any one of them with collagen having a desired degradation rate.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: March 29, 2016
    Inventor: Celso Tello
  • Patent number: 9289428
    Abstract: The present embodiments provide for sustained release formulations of antioxidants that are useful in treating afflictions of the eye and tumors.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: March 22, 2016
    Assignee: RAMSCOR, INC.
    Inventors: Vernon G. Wong, Louis L. Wood, Carol Wood
  • Patent number: 9238094
    Abstract: A bimodal bioabsorbable polymer composition. The composition includes a first amount of a bioabsorbable polymer polymerized so as to have a first molecular weight distribution; a second amount of said bioabsorbable polymer polymerized so as to have a second molecular weight distribution having a weight average molecular weight between about 10,000 to about 50,000 Daltons, the weight average molecular weight ratio of said first molecular weight distribution to said second molecular weight distribution is at least about two to one; wherein a substantially homogeneous blend of said first and second amounts of said bioabsorbable polymer is formed in a ratio of between about 50/50 to about 95/5 weight/weight percent. Also disclosed are a medical device, a method of making a medical device and a method of melt blowing a semi-crystalline polymer blend.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 19, 2016
    Assignee: Ethicon, Inc.
    Inventors: Sasa Andjelic, Benjamin D. Fitz, Jianguo Jack Zhou
  • Patent number: 9233070
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: January 12, 2016
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Patent number: 9173980
    Abstract: A bimodal bioabsorbable polymer composition. The composition includes a first amount of a bioabsorbable polymer polymerized so as to have a first molecular weight distribution; a second amount of said bioabsorbable polymer polymerized so as to have a second molecular weight distribution having a weight average molecular weight between about 10,000 to about 50,000 Daltons, the weight average molecular weight ratio of said first molecular weight distribution to said second molecular weight distribution is at least about two to one; wherein a substantially homogeneous blend of said first and second amounts of said bioabsorbable polymer is formed in a ratio of between about 50/50 to about 95/5 weight/weight percent. Also disclosed are a medical device, a method of making a medical device and a method of melt blowing a semi-crystalline polymer blend.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 3, 2015
    Assignee: Ethicon, Inc.
    Inventors: Sasa Andjelic, Benjamin D. Fitz
  • Publication number: 20150140062
    Abstract: Intraocular implants may include a corticosteroid and a biodegradable polymer associated with the corticosteroid to facilitate the release of the corticosteroid into an eye for a period of time. In some embodiments, ocular conditions, such as diabetic macular edema can be treated through administration of an intraocular implant including a corticosteroid and a biodegradable polymer associated with the corticosteroid to the eye of a human at a frequency of about once every six months to about once a year.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • Publication number: 20150118279
    Abstract: Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.
    Type: Application
    Filed: October 31, 2014
    Publication date: April 30, 2015
    Inventors: Alazar N. Ghebremeskel, Michael R. Robinson
  • Publication number: 20150104491
    Abstract: The present invention provides a sustained release implant for intraocular use to treat elevated intraocular pressure, which implant is configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (IOP), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient and said implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive agent into the eye for a period of time of between 14 days and 365 days.
    Type: Application
    Filed: September 10, 2014
    Publication date: April 16, 2015
    Inventors: Ruiwen Shi, Patrick M. Hughes, James A. Burke, Michael R. Robinson, Hui Liu
  • Patent number: 8969415
    Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 10 days and one year or longer.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, Wendy M. Blanda, Patrick M. Hughes, Guadalupe Ruiz, Werhner C. Orilla, Scott M. Whitcup, Devin F. Welty, Joan-En Lin, Lon T. Spada
  • Patent number: 8962009
    Abstract: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: February 24, 2015
    Assignee: Allergan, Inc.
    Inventors: Glenn T. Huang, Thierry Nivaggioli
  • Publication number: 20150044270
    Abstract: Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or IOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient.
    Type: Application
    Filed: October 23, 2014
    Publication date: February 12, 2015
    Inventors: Peter J. McDonnell, Yasin A. Khan, Samuel K. Lai, Renata T. Kashiwabuchi, Ashley Behrens, Justin S. Hanes
  • Patent number: 8945600
    Abstract: Provided are methods of delivering at least one pharmaceutical agent to the central nervous system (CNS) of a subject, methods of treating a neurological disorder or pain in a subject that include administering at least one pharmaceutical agent onto a SEM graft in the skull base of the subject. Also provided are methods of treating a neurological disorder or pain in a subject that include forming a SEM graft in the skull base of the subject and administering at least one pharmaceutical agent onto the SEM graft in the skull base of the subject. Also provided are methods of forming a SEM graft in the skull base of a subject, compositions for administration onto a SEM graft in the skull base or into an endonasal reservoir or endonasal reservoir device in a subject, and devices for administering such compositions onto a SEM graft in the skull base of a subject.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: February 3, 2015
    Assignee: Massachusetts Eye & Ear Infirmary
    Inventor: Benjamin S. Bleier
  • Patent number: 8927005
    Abstract: Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: January 6, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
  • Patent number: 8911768
    Abstract: Methods for treating and preventing retinopathic conditions by administering an anti-VEGF compound to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: December 16, 2014
    Assignee: Allergan, Inc.
    Inventors: Scott M. Whitcup, David A. Weber
  • Patent number: 8911767
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: December 16, 2014
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • Patent number: 8906406
    Abstract: The invention relates to a mucoadhesive medicinal preparation for administering active substances in veterinary or humane medicine, containing at least one active substance, which preparation is characterized in that it is a mucoadhesive matrix disintegratable in aqueous media, which matrix contains at least one matrix-forming polymer and wherein at least one active substance is dissolved or dispersed, and in that the said preparation disintegrates or erodes within maximally 15 minutes after introduction in an aqueous medium or in body fluids, or in that the preparation initially gels within maximally 15 min after its introduction in an aqueous medium or in body fluids, and disintegrates or erodes within maximally 30 min after said introduction.
    Type: Grant
    Filed: February 8, 2002
    Date of Patent: December 9, 2014
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Tina Rademacher, Frank Seibertz, Petra Brandt, Markus Krumme, Christian Von Falkenhausen
  • Patent number: 8900622
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: December 2, 2014
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • Publication number: 20140341968
    Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 10 days and one year or longer.
    Type: Application
    Filed: August 1, 2014
    Publication date: November 20, 2014
    Inventors: Michael R. Robinson, Wendy M. Blanda, Patrick M. Hughes, Guadalupe Ruiz, Werhner C. Orilla, Scott M. Whitcup, Lon T. Spada, Devin F. Welty, Joan-En Lin
  • Patent number: 8877229
    Abstract: Formulations for controlled, sustained release of biologically active agents for the treatment of ocular disorders have been developed. These formulations are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof. The microparticles are characterized by low burst levels and efficient drug loading and sustained release.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: November 4, 2014
    Assignee: Eyetech Inc.
    Inventors: Kathleen M. Campbell, Pericles Calias, Gary P. Cook, Mary A. Ganley
  • Publication number: 20140322295
    Abstract: Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. The steroid and auxiliary agent may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants containing the steroid and an auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the side effects otherwise accompanying steroid use.
    Type: Application
    Filed: July 7, 2014
    Publication date: October 30, 2014
    Inventors: Glenn T. Huang, Thierry Nivaggioli, Lon T. Spada, Hiroshi Sugimoto, Wendy M. Blanda, James N. Chang, Orest Olejnik
  • Patent number: 8871241
    Abstract: An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as “coatings,” “skins,” or “outer layers”). In certain embodiments, the device is formed by extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles.
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: October 28, 2014
    Assignee: pSivida US, Inc.
    Inventors: Kang-Jye Chou, Hong Guo, Paul Ashton, Robert W. Shimizu, David A. Watson
  • Patent number: 8852652
    Abstract: Provided, among other things, is a method of treating or ameliorating an indication of mucosal or adjacent tissue comprising periodically applying to mucosa at or adjacent to disease affected tissue a rinse comprising: an effective amount of appropriate composition of herbal bioactive comprising active(s) of one or more of Sambucus nigra, Centella asiatica or Echinacea purpurea; an antimicrobially effective amount of a quaternary ammonium surfactant; and optionally a polymer or mixture of polymers effective to coat said tissue and entrap said extract(s).
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: October 7, 2014
    Assignee: Izun Pharmaceuticals, Inc.
    Inventors: Zvi G. Loewy, William Zev Levine, Aron J. Saffer
  • Patent number: 8846073
    Abstract: Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: September 30, 2014
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, James N. Chang, Michelle Luu
  • Publication number: 20140271780
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Allergan, Inc.
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Liu, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • Publication number: 20140234390
    Abstract: Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.
    Type: Application
    Filed: March 18, 2014
    Publication date: August 21, 2014
    Applicant: ALLERGAN, INC.
    Inventors: Jane-Guo Shiah, Chetan Pujara
  • Publication number: 20140234389
    Abstract: Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.
    Type: Application
    Filed: February 14, 2014
    Publication date: August 21, 2014
    Applicant: Allergan, Inc.
    Inventors: Jane-Guo Shiah, Chetan Pujara
  • Patent number: 8802128
    Abstract: Biocompatible intraocular implant systems are formulated for discontinuous or intermittent release of therapeutic levels of a therapeutic agent (such as a steroid) to minimize development of side effects associated with continuous or long term use of such agent. The implant system may comprise one or more implant, and preferably, although not necessarily, also contains an auxiliary agent having an activity effective to lessen at least one side effect associated with said therapeutic agent compared to the use of an otherwise identical implant system lacking said auxiliary agent. The implants containing the therapeutic agent and auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the ocular side effects otherwise accompanying the use of such therapeutic agent.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: August 12, 2014
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, Scott M. Whitcup
  • Patent number: 8802129
    Abstract: Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: August 12, 2014
    Assignee: Allergan, Inc.
    Inventors: Scott M. Whitcup, David A. Weber